The global antibody fragments market was valued at US$ 15,450.0 Mn 2018 and is expected to reach US$ 29,673.3 Mn 2026, growing at a CAGR of 8.5% during the forecast period.
Antibody fragments are fragments obtained after the papain or pepsin digestion of full length antibodies. The antibody fragments market is still in its nascent stages and most of the research related to antibody fragments currently undertaken is targeted towards cancer and related diseases.
The growth of the antibody fragments market is primarily driven by the increasing prevalence of target diseases, the advantages of antibody fragments over full length antibodies, and the increasing investment in R&D. However the market growth is expected to be hindered by the strict regulatory guidelines for the approval of antibody fragments, and the obstacles in purification of antibody fragments.
Currently there are very few companies are marketing their antibody fragments products. However, many players are investing in the R&D of antibody fragments and related products. The rich clinical pipeline of antibody fragments products is also expected to drive the growth of the antibody fragments market.
The global antibody fragments market report covers an in-depth analysis of the market including statistical and subjective data points, along with the key market drivers and opportunities & restraints that have positive or negative effects on the overall global market. An in-depth analysis of the regional and country level market at the various segment and sub-segment levels has been provided. The report comprises a competitive analysis of the key players functioning in the market and covers in-depth data related to the competitive landscape of the market and the recent strategies & product launches that will assist or affect the market in the near future.
The F(ab) antibody fragments dominate the market throughout the forecast period
Based on type, the antibody fragments market has been segmented into F(ab) fragments, F(ab’)2 fragments, Single-chain Variable Fragments (scFvs) and Single Domain Antibody Fragments (sdAbs) and others. The F(ab) and F(ab’)2 are the first generation of antibody fragments. The first generation of antibody fragments together accounted for more than 50% of the share in the base year.
While scFvs accounted for a very small share in the market they are expected to grow at a CAGR of more than 9% during the forecast period. The first sdAb has been approved for use in 2018 in the European Union and in February 2019 by the US FDA. Size of the second and third generation of antibody fragments is their most important advantage over the first generation of antibody fragments. This is expected to drive the growth of scFvs and sdAbs segment of the market.
Based on application, the cancer segment is expected to grow at a CAGR of around 8% during the forecast period
Based on application, the market has been segmented into cancer, immunodeficiencies and others. Cancer application segment accounts of the largest share in the market and is expected to grow at a CAGR of around 8% during the forecast period. The major factors that are driving the growth of this
currently undergoing clinical trials are targeted towards cancer and related diseases.
According to the International Agency for Research on Cancer, the incidence of cancer is expected to rise from 18.1 million in 2018 to around 22 million by the year 2026. Antibody fragments will prove to a valuable treatment for cancer owing to the small size of the fragments which aid better penetration in the tumor.
North America to dominate the antibody fragments market throughout the forecast period
North America accounted for more than 35% share of the global antibody fragments market in 2018 and is expected to dominate the market throughout the forecast period. The major factors for the dominance of this region in the antibody fragments market include the high prevalence of target diseases in this region, the favourable reimbursement scenario, and high quality of the healthcare infrastructure.
The market is increasingly witnessing growth opportunities from emerging countries. Asia-Pacific is expected to grow at the highest CAGR during the forecast period. The rising prevalence of target disease, increasing healthcare expenditure and the increasing demand of quality healthcare are some of the major factors driving the growth of this market.
Company Profiles and Competitive Intelligence:
The major players operating in the antibody fragments market are Pfizer Inc. (US), Albynx, a Sanofi Company (Belgium), Novartis AG (Switzerland), and Genentech, a member of Roche Group (United States). While many other companies such as AbbVie Inc., Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly have antibody fragment products in their pipeline and are expected to enter this market in the future.
Most of the companies are increasingly investing in the research and development of antibody fragments for various indications.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Approach Adopted
1.3.4.1 Top-Down Approach
1.3.4.2 Bottom-Up Approach
1.3.5 Assumptions
1.4 Market Segmentation Scope
Chapter 2 Executive Summary
2.1 Market Summary
2.1.1 Global Antibody Fragments Market, 2016-2026, (US$ Mn)
2.1 Market Snapshot: Global Antibody Fragments Market
2.2 Market Dynamics
2.3 Global Antibody Fragments Market, by Segment, 2018
2.3.1 Global Antibody Fragments Market, by Type, 2018 (US$ Mn)
2.3.2 Global Antibody Fragments Market, by Application, 2018 (US$ Mn)
2.3.3 Global Antibody Fragments Market, by Region, 2018 (US$ Mn)
2.4 Premium Insights
2.4.1 Antibody Fragments Market In Developed Vs. Developing Economies, 2018 vs 2026
2.4.2 Global Antibody Fragments Market: Regional Life Cycle Analysis
Chapter 3 Market Dynamics
3.1 Market Overview
3.2 Market Drivers
3.2.1 Increasing prevalence of targets disease
3.2.2 Advantages over full length Antibodies
3.2.3 Increasing investment in R&D by leading players
3.3 Market Restraints
3.3.1 Strict Regulatory Guidelines
3.3.2 Obstacles in manufacturing and purification of antibody fragments
3.4 Market Opportunities
3.4.1 Increasing demand from emerging countries
3.4.2 Opportunity 2
Chapter 4 Global Antibody Fragments Market, by Type
4.1 Market Overview, by Type
4.1.1 Global Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
4.1.2 Incremental Opportunity, by Type, From 2018-2026
4.2 F(ab) Fragments
4.2.1 Global Antibody Fragments Market, by F(ab) Fragments, 2016-2026, (US$ Mn)
4.3 F(ab’)2 Fragments
4.3.1 Global Antibody Fragments Market, by F(ab’)2 Fragments, 2016-2026, (US$ Mn)
4.4 Single-chain Variable Fragments (scFv)
4.4.1 Global Antibody Fragments Market, by Single-chain Variable Fragments (scFv), 2016-2026, (US$ Mn)
4.5 Single Domain Antibody Fragments (sdAb)
4.5.1 Global Antibody Fragments Market, by Single Domain Antibody Fragments (sdAb), 2016-2026, (US$ Mn)
Chapter 5 Global Antibody Fragments Market, by Application
5.1 Market Overview, by Application
5.1.1 Global Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
5.1.2 Incremental Opportunity, by Application, From 2018-2026
5.2 Cancer
5.2.1 Global Antibody Fragments Market, by Cancer, 2016-2026, (US$ Mn)
5.3 Immunodeficiencies
5.3.1 Global Antibody Fragments Market, by Immunodeficiencies, 2016-2026, (US$ Mn)
5.4 Other Applications
5.4.1 Global Antibody Fragments Market, by Other Applications, 2016-2026, (US$ Mn)
Chapter 6 Global Antibody Fragments Market, by Region
6.1 Market Overview, by Region
6.1.1 Global Antibody Fragments Market, by Region, 2016-2026, (US$ Mn)
6.2 Attractive Investment Opportunity, by Region, 2018
6.3 North America Antibody Fragments Market
6.3.1 North America Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
6.3.2 North America Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
6.3.3 United States Country Profile
6.3.3.1 United States Antibody Fragments Market, 2016-2026 (US$ Mn)
6.3.4 Canada Country Profile
6.3.4.1 Canada Antibody Fragments Market, 2016-2026 (US$ Mn)
6.4 Europe Antibody Fragments Market
6.4.1 Europe Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
6.4.2 Europe Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
6.4.3 United Kingdom Country Profile
6.4.3.1 United Kingdom Antibody Fragments Market, 2016-2026 (US$ Mn)
6.4.4 Germany Country Profile
6.4.4.1 Germany Antibody Fragments Market, 2016-2026 (US$ Mn)
6.4.5 France Country Profile
6.4.5.1 France Antibody Fragments Market, 2016-2026 (US$ Mn)
6.4.6 Rest of Europe
6.4.6.1 Rest of Europe Antibody Fragments Market, 2016-2026 (US$ Mn)
6.5 Asia Pacific Antibody Fragments Market
6.5.1 Asia-Pacific Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
6.5.2 Asia-Pacific Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
6.5.3 China Country Profile
6.5.3.1 China Antibody Fragments Market, 2016-2026 (US$ Mn)
6.5.4 Japan Country Profile
6.5.4.1 Japan Antibody Fragments Market, 2016-2026 (US$ Mn)
6.5.5 India Country Profile
6.5.5.1 India Antibody Fragments Market, 2016-2026 (US$ Mn)
6.5.6 Rest of Asia Pacific
6.5.6.1 Rest of Asia Pacific Antibody Fragments Market, 2016-2026 (US$ Mn)
6.6 Rest of the World Antibody Fragments Market
6.6.1 Rest of the World Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
6.6.2 Rest of the World Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
6.6.3 Latin America
6.6.3.1 Latin America Antibody Fragments Market, 2016-2026 (US$ Mn)
6.6.4 Middle East & Africa
6.6.4.1 Middle East & Africa Antibody Fragments Market, 2016-2026 (US$ Mn)
Chapter 7 Competitive Intelligence
7.1 Top 5 Players Comparison
7.2 Market Positioning of Key Players, 2018
7.3 Market Players Mapping
7.3.1 By Type
7.3.2 By Application
7.3.3 By Region
7.4 Strategies Adopted by Key Market Players
7.5 Recent Developments in the Market
7.5.1 Mergers & Acquisitions, Partnership, New Product Developments
7.6 Operational Efficiency Comparison by Key Players
Chapter 8 Company Profiles
8.1 Genentech
8.1.1 Genentech Overview
8.1.2 Key Stakeholders/Person in Genentech
8.1.3 Genentech Products Portfolio
8.1.4 Genentech Financial Overview
8.1.5 Genentech News/Recent Developments
8.2 Pfizer Inc.
8.2.1 Pfizer Inc. Overview
8.2.2 Key Stakeholders/Person in Pfizer Inc.
8.2.3 Pfizer Inc. Products Portfolio
8.2.4 Pfizer Inc. Financial Overview
8.2.5 Pfizer Inc. News/Recent Developments
8.3 Novartis AG
8.3.1 Novartis AG Overview
8.3.2 Key Stakeholders/Person in Novartis AG
8.3.3 Novartis AG Products Portfolio
8.3.4 Novartis AG Financial Overview
8.3.5 Novartis AG News/Recent Developments
8.4 Albynx
8.4.1 Albynx Overview
8.4.2 Key Stakeholders/Person in Albynx
8.4.3 Albynx Products Portfolio
8.4.4 Albynx Financial Overview
8.4.5 Albynx News/Recent Developments
TABLE 1 Market Snapshot: Global Antibody Fragments Market Value
TABLE 2 Global Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
TABLE 3 Global Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
TABLE 4 Global Antibody Fragments Market, by Region, 2016-2026 (US$ Mn)
TABLE 5 North America Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
TABLE 6 North America Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
TABLE 7 Europe Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
TABLE 8 Europe Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
TABLE 9 Asia-Pacific Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
TABLE 10 Asia-Pacific Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
TABLE 11 Rest of the World Antibody Fragments Market, by Type, 2016-2026 (US$ Mn)
TABLE 12 Rest of the World Antibody Fragments Market, by Application, 2016-2026 (US$ Mn)
TABLE 13 Top 5 Players Comparison
TABLE 14 Market Players Mapping – By Type
TABLE 15 Top Players Market Mapping – By Application
TABLE 16 Top Players Market Mapping – By Region
TABLE 17 Strategies Adopted by Key Market Players
TABLE 18 Mergers & Acquisitions, Partnership, New Product Developments
TABLE 19 Genentech Overview
TABLE 20 Key Stakeholders/Person in Genentech
TABLE 21 Genentech Product Portfolio
TABLE 22 Genentech News/Recent Developments
TABLE 23 Pfizer Inc. Overview
TABLE 24 Key Stakeholders/Person in Pfizer Inc.
TABLE 25 Pfizer Inc. Product Portfolio
TABLE 26 Pfizer Inc. News/Recent Developments
TABLE 27 Novartis AG Overview
TABLE 28 Key Stakeholders/Person in Novartis AG
TABLE 29 Novartis AG Product Portfolio
TABLE 30 Novartis AG News/Recent Developments
TABLE 31 Albynx Overview
TABLE 32 Key Stakeholders/Person in Albynx
TABLE 33 Albynx Product Portfolio
TABLE 34 Albynx News/Recent Developments
